Gillies M, Arnold J, Bhandari S, et al. - In this retrospective, comparative, interventional case series, researchers reported and compared 10-year treatment outcomes of vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD) from Australia and New Zealand (ANZ) and Switzerland. Investigators found that the mean VA in 132 eyes from ANZ that completed 10 years of treatment dropped from baseline by 0.9 letters with 42% reaching ≥ 20/40, whereas the 37 eyes from Switzerland lost 14.9 letters with 35% reaching ≥ 20/40. When appropriate care is provided, eyes with nAMD may achieve acceptable long-term visual outcomes. As previously feared, central macular atrophy does not develop universally in eyes on long-term treatment with VEGF inhibitors. Visual outcomes were better in eyes from ANZ, possibly because more injections were obtained.